Literature DB >> 15073469

Fixed-dose combination therapy--is it time for this approach to hypertension and dyslipidemia management?

Domenic A Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15073469      PMCID： PMC8109482          DOI： 10.1111/j.1524-6175.2004.02874.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  12 in total

Review 1.  State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action.

Authors:  A Faggiotto; R Paoletti
Journal:  Hypertension       Date:  1999-10       Impact factor: 10.190

2.  Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine.

Authors:  D J Hyman; V N Pavlik
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

3.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 4.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.

Authors:  Eyal Leibovitz; Maya Beniashvili; Reuven Zimlichman; Angela Freiman; Marina Shargorodsky; Dov Gavish
Journal:  Am J Hypertens       Date:  2003-09       Impact factor: 2.689

8.  The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs.

Authors:  Jarir Atthobari; Taco B M Monster; Paul E de Jong; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 9.  Interactions between hypercholesterolemia and hypertension: implications for therapy.

Authors:  Claudio Borghi
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

Review 10.  Statins for primary prevention: strategic options to save lives and money.

Authors:  James Shepherd
Journal:  J R Soc Med       Date:  2004-02       Impact factor: 18.000
View more
  1 in total

1.  A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.

Authors:  Woohyeun Kim; Kiyuk Chang; Eun Joo Cho; Jeong-Cheon Ahn; Cheol Woong Yu; Kyoung-Im Cho; Yong-Jin Kim; Duk-Hyun Kang; Seok-Yeon Kim; Sang-Hak Lee; Ung Kim; Shin-Jae Kim; Young Keun Ahn; Chang Hoon Lee; Jin Ho Shin; Mikyung Kim; Chang Gyu Park
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.